Evaluation of antigen-specific immunoglobulin g responses in pulmonary tuberculosis patients and contacts by 김영미 et al.
Evaluation of Antigen-Specific Immunoglobulin G Responses in
Pulmonary Tuberculosis Patients and Contacts
Yun-Gyoung Hur,a Ahreum Kim,a Young Ae Kang,b An Sik Kim,c Dae Yeon Kim,c Yeun Kim,d Youngmi Kim,a Hyeyoung Lee,d
Sang-Nae Choa
Department of Microbiology and Institute of Immunology and Immunological Diseases, Brain Korea 21 Plus Project for the Medical Sciences, Yonsei University College of
Medicine, Seoul, Republic of Koreaa; Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Koreab; National
Mokpo Hospital, Mokpo, Jeonnam, Republic of Koreac; Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Gangwon,
Republic of Koread
This study aimed to evaluate the serodiagnostic potential of immunoglobulin G (IgG) responses to Mycobacterium tubercu-
losis antigens in pulmonary tuberculosis (TB) patients, recent TB contacts with latent TB infection (LTBI), and healthy subjects.
Infections were assessed using tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, drug susceptibility testing, andmo-
lecular genotyping of clinical isolates. Serum IgG responses to selectiveM. tuberculosis antigens, including the 38-kDa and 16-
kDa antigens, lipoarabinomannan (LAM), and recombinant early secreted antigen target 6 kDa (ESAT-6) and culture filtrate
protein 10 kDa (CFP-10), were determined.We found that the serum IgG responses to all antigens might differentiate between
active TB and LTBI, with LAM having the highest diagnostic value (area under the curve [AUC] of 0.7756, P< 0.001). Recurrent
TB cases showed significantly higher IgG responses to 38 kDa, CFP-10 (P< 0.01), and LAM (P< 0.05) than new cases, andmale
patients had higher levels of antigen-specific IgG than females (P< 0.05). Conversely, drug resistance and patient body mass
index did not affect IgG responses (P> 0.05). LAM-specific IgG responses differentiated between acid-fast bacillus (AFB) smear-
positive and -negative patients (P< 0.01), whereas antigen-specific IgG responses did not vary with theM. tuberculosis genotype
(P> 0.05). Significantly higher IgG responses to 38 kDa and 16 kDa were observed in AFB smear-negative patients than in con-
trols. These results suggest that assessment of serum IgG responses to selective purifiedM. tuberculosis antigens may help im-
prove the diagnosis of active TB, particularly for sputum smear-negative patients or recurrent cases, and these may also help to
differentiate between active TB and LTBI.
Tuberculosis (TB), an infectious disease caused by Mycobacte-rium tuberculosis, remains a major global health problem and
is a significant cause of morbidity and mortality worldwide (1). It
is estimated that nearly one-third of the world’s population is
latently infected with M. tuberculosis (2), and around 8.6 million
new cases were reported to the World Health Organization
(WHO) globally in 2012 (1). About 3.6% of new cases are caused
by multidrug-resistant (MDR) strains, and the levels of MDR-TB
were found to be higher (20%) in patients previously treated for
TB (3). Notably, a high risk of multidrug resistance and epidemic
spread of TB in Asia are associated with theM. tuberculosis Beijing
strain (4, 5).
Current TB diagnostics rely mostly on identification ofM. tu-
berculosis clinical isolates by acid-fast bacillus (AFB) staining or
culture (6). Although AFB smear staining allows rapid detection
of mycobacteria in clinical specimens, it has relatively low sensi-
tivity, with a greater failure rate in children and immunocompro-
mised groups, such as the elderly and patients with AIDS (6). The
culture method is more sensitive than AFB staining, but it takes
several weeks to obtain results and requires laboratory facilities
that may be unavailable in resource-limited settings (6). Immu-
nological approaches, such as the tuberculin skin test (TST) and
gamma interferon (IFN-) release assay (IGRA), have also been
developed for detecting latent TB infection (LTBI). The IGRA has
higher specificity than the TST due to the use of M. tuberculosis-
specific peptide antigens, such as early secreted antigen target 6
kDa (ESAT-6), culture filtrate protein 10 kDa (CFP-10), and
TB7.7 (7, 8). However, both the TST and IGRA failed to discrim-
inate between LTBI and active TB in areas with a high burden of
TB (9, 10), indicating that there is no gold standard for the differ-
ential diagnosis between active TB and LTBI.
Development of a serodiagnostic method for TB diagnosis
has garnered considerable interest, as these assays are both sim-
ple and cost-effective; however, efforts have been hampered by
inconsistent results (11). Notably, while serodiagnosis of TB by
combining immunoglobulin classes was suggested as a useful
point-of-care test in South Africa (12), poor performance of
the commercial serological tests for diagnosing pulmonary TB
was reported in India (13), and to date, no commercial serodi-
agnostic tests have demonstrated acceptable sensitivity and
specificity for routine laboratory use. In previously developed
tests, these have varied, depending on the recombinant anti-
gens tested (14), and changes in antibody levels following suc-
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cessful anti-TB treatment also varied with different antigens
(15–17). Inconsistent M. tuberculosis antigen-specific antibody
titers were also found in populations with various levels of M.
tuberculosis exposure (18). Moreover, antibody responses were
much stronger in sputum smear-positive TB than in sputum
smear-negative TB (19, 20). These reports indicate that when TB
serodiagnostics are being developed, factors such as the antigens
utilized, population variation, stage of infection, and bacillary
load should be considered.
Based on the reports showing significantly higher sensitivi-
ties of the IgG test compared with the IgM, IgA, or IgG/IgM
tests in response to mycobacterial antigens (21, 22), we aimed
to evaluate the IgG responses to five different M. tuberculosis
antigens, 38-kDa and 16-kDa antigens, ESAT-6, CFP-10, and
lipoarabinomannan (LAM), in the sera of active TB patients, TB
contacts with LTBI, and controls. We correlated antigen-specific
IgG responses with infection state, TB recurrence, drug resistance,
bacterial burden,M. tuberculosis genotype, and patient bodymass
index (BMI) and gender, in order to identify candidate antigens
with clinical value for TB diagnosis and elucidate factors that may
influence M. tuberculosis-specific IgG responses in TB patients.
MATERIALS AND METHODS
Enrollment of study subjects. In total, 159 pulmonary TB patients, 51
recent TB contacts, and 133 healthy subjects were recruited at two
hospitals in South Korea. From February 2011 to December 2012, 73
TB patients (mean age, 46 years) were enrolled at Mokpo National
Hospital, and from November 2010 to December 2013, 86 TB patients
(mean age, 32 years), 51 asymptomatic TB contacts (mean age, 44
years), and 133 healthy subjects (mean age, 31 years) were enrolled at
Severance Hospital (Fig. 1). Informed written consent was obtained
from all participants for interviews and for diagnostic and immunolog-
ical tests. Active pulmonary TB was diagnosed by confirmation ofM. tuber-
culosis strains from sputum smear/culture and chest X-ray (7), and the
genotypes of infectingM. tuberculosis strains were confirmed by molecu-
lar genotyping (23) in 94 patients. The LTBI and control groups were
defined based on results of TSTs and QuantiFERON-TB Gold In-Tube
(QFT-IT) tests (7, 8). Among the 51 TB contacts, 26 showed positive
IFN- responses in QFT-IT tests; double-positive responses for TSTs
(10 mm) and QFT-IT tests were observed in 19 of the 26 TB contacts,
while 7 of the 26 TB contacts had negative TST results (10 mm). The
control group consisted of 54 individuals with double-negative responses
for TSTs (10 mm) and QFT-IT tests among the 133 healthy individuals
who had never had contact with TB patients. Subjects taking immuno-
suppressants or those with cancer, diabetes, or renal disease were ex-
cluded. Our final study population consisted of 94 TB patients, 26 con-
tacts with LTBI, and 54 healthy controls (Fig. 1).
Ethical approval was granted by the Mokpo National Hospital Ethics
Review Committee (approval number 2010-001) and the Severance Hos-
pital Ethics Review Committee (approval number 4-2010-0213).
TSTs. An intradermal injection of tuberculin purified protein deriva-
tive (0.1 ml of RT-23; Statens Serum Institute, Copenhagen, Denmark)
was given to all participants. Induration sizes were determined at 48 and
72 h, and measurements10 mm were classified as positive.
Preparation of blood samples. Serum samples were separated by cen-
trifugation from 4 ml of blood (Vacuette serum tube; Greiner Bio-One
GmbH, Frickenhausen, Germany). For QFT-IT tests, a total of 3 ml of
blood was collected directly into each of three QFT-IT tubes: nil, M. tu-
berculosis antigen (Ag) tube (ESAT-6, CFP-10, and TB7.7 peptide anti-
gens), and mitogen (phytohemagglutinin [PHA] (Cellestis, CA, USA).
Plasma was harvested after incubation at 37°C for 24 h, and IFN- en-
zyme-linked immunosorbent assays (ELISAs) were performed according
to the manufacturer’s protocol (QuantiFERON-TB Gold, Cellestis).
Molecular genotyping of M. tuberculosis. M. tuberculosis genotypes
were determined byM. tuberculosisBeijing genotyping (Optipham-M&D,
Wonju, South Korea) based on large-sequence polymorphism analysis
(23). Briefly, genomic DNAwas extracted by boiling a mycobacterial sus-
pension scraped fromLowenstein-Jensenmedia slants (BectonDickinson
and Company, MD, USA) in 400 l buffer (10 mM Tris-HCl [pH 8.0], 1
mM EDTA). DNA served as a template for gene amplification using a
Veriti 96-well fast thermal cycler (Applied Biosystems, Life Technologies,
CA, USA), and products were analyzed using agarose gel electrophoresis.
Purification of recombinant protein antigens. The 38-kDa and 16-
kDa antigens were provided by Standard Diagnostics, Inc. (Suwon, South
Korea), and LAM was obtained from the Mycobacteria Research Labora-
tory, Colorado State University (Fort Collins, CO, USA). Vector con-
struction for expression of recombinant ESAT-6 and CFP-10 was per-
formed using the NdeI and BamHI (New England BioLabs, MA, USA)
sites of pET11a_KB, and geneswere amplified fromM. tuberculosisH37Rv
genomicDNA. Plasmids encoding ESAT-6 andCFP-10were transformed
into Escherichia coli BL21(DE3) for protein overexpression, and recombi-
nant proteins were purified using nickel-nitrilotriacetic acid (Ni-NTA)
resin (Qiagen, CA, USA) and fast protein liquid chromatography
(ÄKTAFPLC; GE Healthcare Life Sciences, PA, USA) with a Mono Q
anion-exchange column (GE Healthcare Life Sciences).
Measurement of IgG responses to M. tuberculosis antigens. M. tu-
berculosis antigens were coated in 96-well microplates (Corning Inc., NY,
USA) at 2 g/ml (38 kDa, 16 kDa, ESAT-6, and CFP-10) or 0.1 g/ml
(LAM) in 0.5 M carbonate-bicarbonate buffer overnight at 4°C. Plates
were washed three times in phosphate-buffered saline (PBS) supple-
mented with 0.05% Tween 20 (PBST) and blocked with PBST containing
5% normal goat serum (PBST-NGS) at 37°C for 1 h. Blocked plates were
incubated with human serum samples (1:300 dilution in PBST-NGS) at
37°C for 2 h, washed again with TBST, and incubated with peroxidase-
conjugated anti-human IgG antibody (1:10,000 dilution in PBST-NGS;
Calbiochem, CA, USA) at 37°C for 1 h. Plates were washed again with
TBST, and tetramethylbenzidine (KPL, MD, USA) was added. The reac-
tion was stopped with 2.5 N H2SO4, and the optical density (OD) was
measured at 450 nm using the ELISA microplate reader (Molecular De-
vices, CA, USA).
Statistical analysis. Differential M. tuberculosis antigen-specific IgG
responses in TB patients, contacts with LTBI, and healthy controls were
analyzed by Kruskal-Wallis and Dunn’s multiple comparison tests. The
IgG responses between groups based on TB recurrence, drug resistance,
AFB staining,M. tuberculosis genotype, and patient BMI and gender were
analyzed by Mann-Whitney tests. Diagnostic values of IgG responses to
M. tuberculosis antigens were examined by analysis of receiver operating
characteristic (ROC) curves.
FIG 1 Enrollment of study participants. In total, 159 active TB patients, 51 TB
contacts, and 133 healthy subjects were recruited fromMokpo National Hos-
pital (MNH) and from SeveranceHospital (SH). Of these, the genotypes of the
infecting M. tuberculosis strains were confirmed in 94 TB patients. Based on
QFT-IT tests and TSTs, 26 TB contacts were defined as individuals with LTBI
and 54 normal healthy controls were identified.
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RESULTS
M. tuberculosis antigen-specific IgG responses in active TB,
LTBI, and controls. In order to determine M. tuberculosis anti-
gen-specific IgG responses according to the infection status, IgG
responses were evaluated in active TB, LTBI, and control groups.
We found that active TB patients showed significantly higher IgG
responses than controls to all antigens tested (P  0.001 or P 
0.01) (Fig. 2a). The area under the ROC curve (AUC) for 38 kDa-
specific IgG responses was the highest among the five antigens
(AUC of 0.7695, P  0.001), followed by those for LAM and 16
kDa (Table 1). The sensitivity (73.4%) and specificity (70.4%)
were also highest for 38 kDa-specific IgG responses (Table 1).
Although ESAT-6- and CFP-10-specific IgG responses differed
between the active TB and control groups (Fig. 2a), the low AUCs
(0.7) and sensitivities (55.3% and 51.1%, respectively) of those
responses did not provide diagnostic value (Table 1). Active TB
and LTBI were differentiated by IgG responses to all antigens
tested (P  0.01) (Fig. 2a), with the highest AUC (0.7756, P 
0.001), sensitivity (67.0%), and specificity (80.8%) observed for
LAM-specific responses (Table 1).
M. tuberculosis antigen-specific IgG responses based on his-
tory of TB patients.Of 94 active TB patients, 58 were newly diag-
nosed, and 36 previously had TB. These 36 patients, defined as
recurrent cases, included individuals with relapsed TB after suc-
cessful treatment and those whose initial treatment failed, either
due to self-stop or drug resistance. The IgG responses to all anti-
gens tested were significantly higher in recurrent cases than in
controls (Fig. 2b), and AUC, sensitivity, and specificity values
were higher for recurrent cases than for new cases versus controls
(Table 1). In particular, almost a 2-fold difference was found in
the sensitivity of the CFP-10-specific IgG responses between re-
current (72.2%) and new cases (36.2%) (Table 1). The IgG re-
sponses to 38 kDa, 16 kDa, and LAM also differentiated between
new cases and controls (Fig. 2b).
Effects of drug susceptibility and BMI on IgG responses. A
total of 23 patients were classified with drug-resistantM. tubercu-
losis, including two extensively drug-resistant (XDR) and three
MDRpatients out of 88 patients tested for drug susceptibility. The
IgG responses to all antigens were not significantly different in
these patients than in those with drug-sensitive M. tuberculosis
(P  0.05, data not shown). The M. tuberculosis antigen-specific
IgG responses also did not vary in the 24 patients with BMIs of
18.5 kg/m2 and the 64 patients with BMIs in the normal range
(18.5 kg/m2 BMI 25 kg/m2) (data not shown).
Association between antigen-specific IgG responses and M.
tuberculosis isolates.M. tuberculosis antigen-specific IgGresponses
were analyzed based on the results of AFB smear staining and M.
tuberculosis genotyping. In response to 38 kDa, 16 kDa, ESAT-6,
and CFP-10, we observed no significant differences depending on
AFB smear-staining results in 91 TB patients tested (Fig. 3a).
However, AFB smear-positive patients showed significantly
higher IgG responses to LAMthan thosewith negative results (P
0.01) (Fig. 3a); analysis of the ROC curve in AFB smear-positive
(AUC of 0.8909, P  0.001) and -negative patients (AUC of
0.6857, P  0.001) confirmed these results. Conversely, 38 kDa-
and 16 kDa-specific IgG responses showed good diagnostic values
(AUC of 0.7, P  0.001) in sputum smear-negative patients.
Genotyping revealed that Beijing strains accounted for about 81%
(76/94) of the isolates in our study; however, the antigen-specific
IgG responses did not differ according to strain genotype (P 
0.05) (Fig. 3b).
Influence of gender on IgG responses.We found that the anti-
gen-specific IgG responses were significantly higher inmale (n 64)
than in female (n 30) patients in response to all antigens, with the
exceptionofESAT-6 (Fig. 4).Thedifferenceswereparticularly signif-
icant for 38 kDa- and LAM-specific IgG responses (P  0.001). It
should be noted that the percentages of recurrent cases, drug resis-
tance, and positive AFB smear test results were all more than 2-fold
FIG 2 Antigen-specific IgG responses according to infection state and TB recurrence. (a) TB patients (n  94) had significantly higher IgG responses to all
antigens tested than individuals with LTBI (n 26) and controls (n 54), whereas there were no significant differences in IgG responses between individuals
with LTBI and controls. (b)M. tuberculosis antigen-specific IgG responses were compared between recurrent TB (n 36) and new (n 58) cases. In response
to 38 kDa, CFP-10, and LAM, recurrent cases showed significantly higher IgG responses, as compared to new cases. The IgG responses to 38 kDa and LAM also
differed between new cases and controls, whereas ESAT-6 and CFP-10 did not differentiate between these groups. The median levels of IgG responses are
indicated with horizontal bars in red (*P 0.05; **P 0.01; ***P 0.001).
Hur et al.
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higher inmale patients than in female patients, whilemean age, BMI,
and proportions ofM. tuberculosis genotypes were similar between
the two groups (Table 2).
DISCUSSION
In this study, we found that M. tuberculosis antigen-specific IgG
responses are affected by infection state (active TB versus LTBI),
TB recurrence, bacterial burden, and gender, whereas age, BMI,
and M. tuberculosis genotype had no effect. While considerable
effort has been focused on identifying biomarkers for the differ-
ential diagnosis of LTBI and active TB (9, 24), we observed that
LAM-specific IgG responses reliably differentiated these, suggest-
ing that thismight be an informativemarker for clinical diagnosis.
LAM is a major cell wall component that contributes toM. tuber-
TABLE 1 Analysis of ROC curves for antigen-specific IgG responses in different patient groupsa
Groups and antigens AUC (P value) % sensitivity % specificity Cutoff (OD)
Active TB vs control
38 kDa 0.7695 (0.001) 73.4 70.4 0.015
16 kDa 0.7535 (0.001) 71.3 70.4 0.010
ESAT-6 0.6544 (0.01) 55.3 70.4 0.021
CFP-10 0.6643 (0.001) 51.1 70.4 0.024
LAM 0.7655 (0.001) 68.1 70.4 0.189
Active TB vs LTBI
38 kDa 0.7064 (0.01) 58.5 73.1 0.027
16 kDa 0.7535 (0.001) 64.9 73.1 0.012
ESAT-6 0.6966 (0.01) 55.3 73.1 0.021
CFP-10 0.7398 (0.001) 64.9 76.9 0.019
LAM 0.7756 (0.001) 67.0 80.8 0.210
Recurrent case vs control
38 kDa 0.8593 (0.001) 80.6 77.8 0.019
16 kDa 0.8027 (0.001) 75.0 77.8 0.012
ESAT-6 0.6965 (0.01) 63.9 74.1 0.024
CFP-10 0.7744 (0.001) 72.2 72.2 0.025
LAM 0.8498 (0.001) 72.2 74.1 0.237
New case vs control
38 kDa 0.7138 (0.001) 67.2 70.4 0.015
16 kDa 0.7230 (0.001) 67.2 70.4 0.010
ESAT-6 0.6282 (0.05) 50.0 70.4 0.021
CFP-10 0.5959 (0.05) 36.2 70.4 0.024
LAM 0.7131 (0.001) 65.5 70.4 0.189
a AUC, sensitivity, specificity, and cutoff values were calculated by analysis of the ROC curves between the different groups tested. The serum IgG responses to 38 kDa, 16 kDa, and
LAM showed higher sensitivities and specificities to diagnose active TB or LTBI than ESAT-6- and CFP-10-specific IgG responses. The AUC, sensitivity, and specificity were higher
in recurrent cases than in new cases.
FIG 3 Antigen-specific IgG responses depending on identification of M. tuberculosis strains by AFB smear tests and M. tuberculosis genotypes. (a) The median
IgG response to LAMwas significantly higher in patients who showed positive AFB smear test results (AFBve, n 36) than those with negative results (AFB-ve,
n 55). However, all AFB smear-negative patients showed significantly higher IgG responses than controls in response to all antigens tested. (b) The majority
of patients (81%) were infected with theM. tuberculosis Beijing strain, but genotype did not affect antigen-specific IgG responses (n 76 for Beijing strain, n
18 for non-Beijing strain). The median responses are indicated with horizontal bars in red (*P 0.05; **P 0.01; ***P 0.001).
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culosis pathogenicity by arresting host phagosomal maturation
and blocking T cell proliferation (25). We found that only LAM-
specific IgG responses differed between AFB smear-positive and
-negative TB patients (P  0.01), suggesting that these are more
associated with bacillary load than the other antigens tested.
Many studies have focused on identifying novel antigens to
improve the sensitivities and specificities of current TB diag-
nostics, particularly for sputum smear-negative patients or
those incapable of producing sputum. In our study, approxi-
mately 60.4% of 94 patients with culture-confirmed TB failed
to identify M. tuberculosis by the AFB smear test. We observed
that IgG responses to the 38-kDa antigen did not vary based on
sputum smear results; however, both smear-positive and -nega-
tive patients showed significantly higher levels of IgG than con-
trols. The 38-kDa antigen is a surface-exposed lipoprotein, which
has previously been exploited for TB serodiagnosis (26). The sen-
sitivities and specificities of serodiagnostic tests based on this an-
tigen have been reported to range from 40 to 89% and from 44 to
100%, respectively, depending on the study population and test
laboratory (26). We observed approximately 70% sensitivity and
specificity, with a good diagnostic value (AUC of 0.7, P 
0.001), for the 38-kDa antigen in both AFB smear-positive and
-negative patients. These data indicate that measuring the IgG
response to the 38-kDa antigen may facilitate early diagnosis of
TB, particularly in sputum smear-negative patients or those un-
able to produce sputum. Recurrent disease with a poor prognosis
has also been associated with high levels of anti-38-kDa antibody
(19), which corroborates our findings showing a high diagnostic
value (AUC of 0.8593, P  0.001) and enhanced sensitivity and
specificity (81% and 78%, respectively) of the 38-kDa antigen in
recurrent cases. The proportion of patients infected with the Bei-
jing strain was about 4 times higher than that of those infected
with non-Beijing strains (81% versus 19.1%); however, this did
not correlate with the antigen-specific IgG responses, perhaps due
to the limited number of XDR/MDR patients in our drug-resis-
tant cohort.
Gender appeared to affect the antigen-specific IgG responses,
although this result is likely due, at least somewhat, to the differ-
ential frequency and severity of TB in male and female patients.
TB rates are approximately twice as high in men as in women,
suggesting that men are more susceptible to TB (1), although the
biological basis for this discrepancy remains unclear. A higher
frequency of exposure to TB in men and other gender-specific
factors might also influence antigen-specific antibody responses.
Sex steroid hormones have been suggested to play a protective role
against mycobacterial infection (27, 28), but their role remains to
be elucidated.
In conclusion, we found that a serodiagnostic test for TB
using 38-kDa and LAM antigens may be developed as a rapid
and economic point-of-care test in resource-limited settings,
particularly for early diagnosis in sputum smear-negative cases
and recurrent cases and for the differential diagnosis between
active TB and LTBI. However, the sensitivities and specificities
of the responses should be enhanced for clinical use in diagno-
sis between active TB and LTBI. Further studies should focus
on improving the sensitivities and specificities of serodiagnos-
tic tests by selecting epitopes to enhance antibody responses
and by assessing combinations of antigens for possible syner-
gistic effects.
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